A Glance Into Training

[Construction]

“Construction has already started. This is not something we dreamed up a few weeks ago,” Bell told AN. “This is has been going on for quite some time. This is a full-blown investment. This is building a body shop. This is unique in a sense we’re building our bodies. We’re serious about having this flexibility and capacity for quite some time here. That’s where the billion-plus (investment figure) comes from.” Oshawa Assembly is GM’s third pickup truck production plant, joining Flint Assembly in Michigan and Fort Wayne Assembly in Indiana. The Flint plant builds the Chevy Silverado HD and GMC Sierra HD , while Fort Wayne handles production of the light duty versions of the two pickups. The Oshawa Assembly plant is unique in that it will build the Silverado HD and Sierra HD alongside the light duty versions of the trucks.

https://gmauthority.com/blog/2020/11/construction-work-begins-at-gm-oshawa-assembly-plant/

[Cars] [Education]

The news from Moderna was hailed as a "game changer" and Pfizer's chief executive described the vaccine achievement as "a great day for science and humanity." As the market revelry at the news continued, attention quickly turned to practical matters given the unprecedented logistical challenge posed by producing and distributing vaccines, should they receive final regulatory approval, to a global population of around 7 billion people. Vaccines need to be produced and transported in specific (and cold) conditions otherwise they can be rendered ineffective; this poses a huge challenge for global drugmakers when it comes more to vaccine distribution. Swiss drugmaker Lonza has partnered with Moderna and says it aims to produce 400 million doses of the vaccine annually. The U.S. firm is aiming for 500 million to 1 billion doses in total for 2021. Anyone receiving the vaccine will require two doses, as with Pfizer's shot, showing how long it could take, with the current manufacturing capacity, to vaccinate internationally. Lonza will produce ingredients within Moderna's vaccine, formally called mRNA-1273, in facilities in the U.S. and Switzerland, where it is headquartered. Company Chairman Albert Baehny told CNBC about the "big challenges" facing drugmakers like his when it comes to scaling up production.

https://www.cnbc.com/2020/11/18/what-are-the-big-challenges-to-mass-producing-a-coronavirus-vaccine.html